Assertio Holdings reported strong third-quarter results driven by the significant pull-forward in Rolvedon sales, culminating in a net product sales increase of over 150% year-over-year.

• Rolvedon net product sales reached $38.6 million, up from $15 million in Q3 2024, bolstered by a strategic pull-forward in sales.
• Adjusted EBITDA improved to $20.9 million, compared to $4.4 million in the same period last year.
• Sympazan sales grew to $2.8 million, reflecting an increase in volume and underscoring the strength of the product's franchise in the market.
• Assertio narrowed its 2025 guidance, accounting for the impact of the Rolvedon transition and competitive headwinds from Indocin and Otrexup.